Latest Controlled Substances Act Stories
RALEIGH, N.C., Feb. 17, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc.
RARITAN, N.J., Jan. 28, 2011 /PRNewswire/ -- New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
Survey of Police and Teachers: Alcohol and Marijuana Most Serious Substance Abuse Facing Teens NEW YORK, Sept.
Upcoming FDA Hearing on Abuse of Cough and Cold Medications Misses the Mark NEW YORK, Sept.
RARITAN, N.J., Aug. 30 /PRNewswire/ -- Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.
LOS ANGELES, Aug. 18 /PRNewswire/ -- On August 9, 2010 Massachusetts passed Chapter 283 of the Acts of 2010, adding Safeguards to the Prescription Monitoring Program and furthering Substance Abuse Education and Prevention.
CHADDS FORD, Pa., Aug.
DETROIT, June 18 /PRNewswire/ -- Today, the Drug Enforcement Administration and U.S.
BALTIMORE, May 7 /PRNewswire/ -- A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTAÂ® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.
AHCA/NCAL Members Testify Before Senate Committee WASHINGTON, March 24 /PRNewswire-USNewswire/ -- The American Health Care Association and the National Center for Assisted Living (AHCA/NCAL) praised Senator Herb Kohl (D-WI) and the other Members of the U.S.
- A person in a secondary role, specifically the second most important character (after the protagonist).